A Phase 3 interventional study of Online Pain Coping Skills Training and Education in Breast Cancer, Arthralgia and Pain, Chronic, sponsored by Northwestern University. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Northwestern University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by Northwestern University — 4 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · Northwestern University.
Among the 64 studies in Breast Neoplasms by Northwestern University, this one has the largest planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 57th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 64 studies in Breast Neoplasms by Northwestern University are open now, in 2 countries. Recruiting first, the newest first:
Northwestern University · Sites in Nigeria
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 24 · Phase 3 3
First in 1998; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 452 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 31 across the 50 interventional studies, 79 across the 7 observational. Of the 47 that completed or were terminated, 15 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
2 of the studies in Breast Neoplasms by Northwestern University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT05931874Northwestern UniversityOptimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are:
Participants can complete all parts of the study at home. They will:
Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects. They will also be given access to an online pain coping skills training program and asked to complete it at home over 8 to 10 weeks. This interactive, web-based program teaches cognitive and behavioral skills that research has shown can reduce pain and pain-related interference with daily activities. The program includes eight sessions that participants will complete at a rate of about 1 per week. Each session takes 35-45 minutes. Participants will be shown how to use the program and can contact the study team if they have any problems with it. Participants who do not have a device capable of accessing the program will be loaned a tablet computer for the study.
Behavioral: Online Pain Coping Skills Training · Other: Education
Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
Other: Education
The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
Change in Brief Pain Inventory pain severity subscale
We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.
Time frame: Change in BPI pain severity from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Brief Pain Inventory pain interference subscale
We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.
Time frame: Change in BPI pain interference from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Brief Pain Inventory pain severity subscale
We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.
Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Brief Pain Inventory pain severity subscale
We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.
Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Brief Pain Inventory pain interference subscale
We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.
Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Brief Pain Inventory pain interference subscale
We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.
Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Hospital Anxiety and Depression Scale
We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.
Time frame: Change in HADS score from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Hospital Anxiety and Depression Scale
We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.
Time frame: Change in HADS score from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Hospital Anxiety and Depression Scale
We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.
Time frame: Change in HADS score from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)
We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.
Time frame: Change in FACT-B total score from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)
We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.
Time frame: Change in FACT-B total score from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)
We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.
Time frame: Change in FACT-B total score from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Medication Adherence Rating Scale
Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.
Time frame: Change in MARS scores from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Medication Adherence Rating Scale
Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.
Time frame: Change in MARS scores from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Medication Adherence Rating Scale
Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.
Time frame: Change in MARS scores from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Use event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)
We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in change in adherence from baseline to each of the post-intervention assessments.
Time frame: Change in MEMS-recorded adherence from baseline to 10-14 weeks post-baseline (Follow up 1)
Probability of optimal adherence using event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)
We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in probability of optimal adherence, using a dichotomous variable using a cutoff of \<80% to identify sub-optimal adherence (where 80% or greater adherence is optimal).
Time frame: Probability of MEMS-recorded optimal adherence from baseline to 10-14 weeks post-baseline (Follow up 3)
Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale
Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.
Time frame: Change in Self-efficacy for pain management from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale
Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.
Time frame: Change in Self-efficacy for pain management from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale
Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.
Time frame: Change in Self-efficacy for pain management from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Pain Catastrophizing Scale
Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing from baseline; change from baseline to post-intervention (follow up 1) will also be examined as a potential mediator of changes in pain severity and interference.
Time frame: Change in PCS scale scores from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Pain Catastrophizing Scale
Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing.
Time frame: Change in PCS scale scores from baseline to 22-24 weeks post-baseline (Follow up 2)
Change in Pain Catastrophizing Scale
Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing.
Time frame: Change in PCS scale scores from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.
Time frame: Change in PROMIS sleep disturbance scores from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.
Time frame: Change in PROMIS sleep disturbance scores from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.
Time frame: Change in PROMIS sleep disturbance scores from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in PROMIS 8-item Sleep-Related Impairment
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.
Time frame: Change in PROMIS sleep-related impairment scores from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in PROMIS 8-item Sleep-Related Impairment
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.
Time frame: Change in PROMIS sleep-related impairment scores from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in PROMIS 8-item Sleep-Related Impairment
Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.
Time frame: Change in PROMIS sleep-related impairment scores from baseline to 34-38 weeks post-baseline (Follow up 3)
Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale
Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.
Time frame: Change in MENQOL scores from baseline to 10-14 weeks post-baseline (Follow up 1)
Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale
Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.
Time frame: Change in MENQOL scores from baseline to 22-26 weeks post-baseline (Follow up 2)
Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale
Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.
Time frame: Change in MENQOL scores from baseline to 34-38 weeks post-baseline (Follow up 3)
Plan to share: No — Data will be shared according to the most recent NIH guidelines for sharing research data (https://grants.nih.gov/grants/policy/data_sharing/). Findings will be disseminated through presentations at national scientific meetings and peer-reviewed manuscripts. We will make our data available for review and/or research to qualified individuals after the main findings from the final dataset are accepted for publication. Individuals requesting data will be asked to describe their goals, data needs and planned analyses including statistical power. Requests will be reviewed by a Data Access Committee made up of the project's key personnel. This committee will evaluate scientific validity, statistical power, overlap with other analyses/publications, and ethical aspects of the proposed use of the data. We will protect the rights and privacy of our study participants by de-identifying the data and taking any other steps necessary to eliminate potential deductive disclosure.
Started Jan 2023 (actual). Primary completion is estimated for Nov 2026, 46 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 46 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.